MedTrace Logo

COVID-19 Child Health Investigation of Latent Disease in Hamburg

NCT04534608 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 6000

Last updated 2020-09-01

No results posted yet for this study

Summary

The study measures infection rates and the presence of antibodies for SARS-CoV-2 (COVID-19) among in- and outpatients of all pediatric hospitals, as well as volunteers aged 0 to 18 years in Hamburg, Germany. Participants with a positive nasopharyngeal swab PCR or a positive antibody test enter the Follow-up phase of 6 months. The follow up includes a PCR and antibody testing of all household contacts at 0, 3 and 6 months, as well as laboratory testing of children to identify immunological, metabolic and genetic risk factors for infection and clinical outcome.

Conditions

Sponsors & Collaborators

  • Altona Children's Hospital

    collaborator OTHER

  • Wilhelmstift Children´s Hospital

    collaborator UNKNOWN

  • Helios Mariahilf Klinik Hamburg

    collaborator UNKNOWN

  • Asklepios Klinik Nord - Heidberg

    collaborator UNKNOWN

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Principal Investigators

  • Ania C Muntau, Professor · Universitätsklinikum Hamburg-Eppendorf

  • Soeren W Gersting, Professor · Universitätsklinikum Hamburg-Eppendorf

  • Thomas Mir, Professor · Universitätsklinikum Hamburg-Eppendorf

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-11
Primary Completion
2020-06-30
Completion
2021-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04534608 on ClinicalTrials.gov